Work

CpG island methylator phenotype (CIMP) and outcome differences for African Americans (AA) and Caucasians (C) treated with FOLFOX4 or the combination with bevacizumab (B) in patients (pts) with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group study E3200.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.3605

Authors: Edith P. Mitchell, Paul J. Catalano, Bruce J. Giantonio, Peter J. O'Dwyer, Neal J. Meropol, Al Bowen Benson, Stanley R. Hamilton

Institutions: Thomas Jefferson University, Sidney Kimmel Cancer Center, Dana-Farber Cancer Institute, Abramson Cancer Center, University of Pennsylvania, University Hospitals Seidman Cancer Center, Case Western Reserve University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601614644

Cites:

Cited by:

Related to: 10